Alliance for Pandemic Preparedness

April 28, 2021

Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study

Category:

Topic:

Keywords (Tags):

  • Among patients with cancer, one dose of the Pfizer-BioNTech vaccine did not elicit a strong antibody response. In a prospective observational study, the proportion of positive anti-S IgG titers measured at 21 days after vaccination was 38% among patients with solid cancers (21/56 patients), 18% among patients with hematological cancer (8/44), and 94% (32/34) among individuals without cancer. Among participants who received a second dose 21 days later and for whom blood samples were available 2 weeks after the second dose, 95% (18/19) of patients with solid cancer, 60% (3/5) of patients with hematological cancers, and 100% of individuals without cancer were seropositive. 

Monin et al. (Apr 27, 2021). Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(21)00213-8